Goldman Sachs Group Begins Coverage on Quest Diagnostics (DGX)

Stock analysts at Goldman Sachs Group started coverage on shares of Quest Diagnostics (NYSE:DGX) in a note issued to investors on Monday, MarketBeat Ratings reports. The firm set a “buy” rating and a $117.00 price target on the medical research company’s stock. Goldman Sachs Group’s price target indicates a potential upside of 8.45% from the stock’s previous close.

A number of other research analysts also recently issued reports on the company. Mizuho set a $103.00 price target on Quest Diagnostics and gave the company a “buy” rating in a report on Thursday, October 19th. Canaccord Genuity boosted their price target on Quest Diagnostics from $100.00 to $105.00 and gave the company a “buy” rating in a report on Thursday, October 26th. Jefferies Group set a $98.00 price target on Quest Diagnostics and gave the company a “hold” rating in a report on Saturday, November 25th. Zacks Investment Research raised Quest Diagnostics from a “sell” rating to a “hold” rating in a report on Monday, November 6th. Finally, Craig Hallum reissued a “hold” rating and issued a $100.00 price target (down from $110.00) on shares of Quest Diagnostics in a report on Tuesday, October 17th. One research analyst has rated the stock with a sell rating, fifteen have given a hold rating and seven have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $107.15.

Shares of Quest Diagnostics (DGX) traded up $1.26 during midday trading on Monday, reaching $107.88. The company had a trading volume of 1,214,503 shares, compared to its average volume of 825,821. The stock has a market capitalization of $14,530.00, a price-to-earnings ratio of 22.48, a P/E/G ratio of 2.06 and a beta of 0.60. Quest Diagnostics has a 52-week low of $90.10 and a 52-week high of $112.96. The company has a current ratio of 1.47, a quick ratio of 1.37 and a debt-to-equity ratio of 0.78.

In other news, SVP Catherine T. Doherty sold 21,294 shares of the company’s stock in a transaction that occurred on Wednesday, January 24th. The stock was sold at an average price of $104.00, for a total transaction of $2,214,576.00. Following the completion of the transaction, the senior vice president now directly owns 90,709 shares of the company’s stock, valued at approximately $9,433,736. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP J. E. Davis sold 63,880 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $98.68, for a total value of $6,303,678.40. Following the transaction, the executive vice president now directly owns 101,423 shares of the company’s stock, valued at $10,008,421.64. The disclosure for this sale can be found here. Corporate insiders own 1.75% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. PGGM Investments increased its position in shares of Quest Diagnostics by 41.7% during the fourth quarter. PGGM Investments now owns 505,900 shares of the medical research company’s stock worth $49,826,000 after purchasing an additional 148,959 shares in the last quarter. BTC Capital Management Inc. increased its position in shares of Quest Diagnostics by 2.8% during the fourth quarter. BTC Capital Management Inc. now owns 44,976 shares of the medical research company’s stock worth $4,427,000 after purchasing an additional 1,215 shares in the last quarter. Advisor Partners LLC increased its position in shares of Quest Diagnostics by 28.5% during the fourth quarter. Advisor Partners LLC now owns 3,115 shares of the medical research company’s stock worth $321,000 after purchasing an additional 691 shares in the last quarter. Commerzbank Aktiengesellschaft FI purchased a new stake in shares of Quest Diagnostics during the fourth quarter worth approximately $206,000. Finally, Sumitomo Mitsui Asset Management Company LTD increased its position in shares of Quest Diagnostics by 311.5% during the fourth quarter. Sumitomo Mitsui Asset Management Company LTD now owns 45,215 shares of the medical research company’s stock worth $4,453,000 after purchasing an additional 34,227 shares in the last quarter. 88.89% of the stock is owned by institutional investors and hedge funds.

WARNING: This article was first posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2018/01/29/goldman-sachs-group-begins-coverage-on-quest-diagnostics-dgx.html.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).

Analyst Recommendations for Quest Diagnostics (NYSE:DGX)



Leave a Reply